S'abonner

Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis - 31/05/12

Doi : 10.1016/j.jaci.2012.03.023 
Carol J. Henderson, PhD, RD a, J. Pablo Abonia, MD a, Eileen C. King, PhD b, Philip E. Putnam, MD, FAAP c, Margaret H. Collins, MD d, James P. Franciosi, MD, MS, MSCE c, Marc E. Rothenberg, MD, PhD a,
a Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 
b Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 
c Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 
d Division of Pathology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 

Corresponding author: Marc E. Rothenberg, MD, PhD, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 7028, Cincinnati, OH 45229-3039.

Abstract

Background

Eosinophilic esophagitis is a chronic, immune-mediated inflammatory disorder that responds to dietary therapy; however, data evaluating the effectiveness of dietary therapeutic strategies are limited.

Objective

This study compared the effectiveness of 3 frequently prescribed dietary therapies (elemental, 6-food elimination, and skin prick and atopy patch–directed elimination diets) and assessed the remission predictability of skin tests and their utility in directing dietary planning.

Methods

A retrospective cohort of proton-pump inhibitor–unresponsive, non–glucocorticoid-treated patients with eosinophilic esophagitis who had 2 consecutive endoscopic biopsy specimens associated with dietary intervention was identified. Biopsy histology and remissions (<15 eosinophils/high-power field) after dietary therapy and food reintroductions were evaluated.

Results

Ninety-eight of 513 patients met the eligibility criteria. Of these 98 patients, 50% (n = 49), 27% (n = 26), and 23% (n = 23) received elemental, 6-food elimination, and directed diets, respectively. Remission occurred in 96%, 81%, and 65% of patients on elemental, 6-food elimination, and directed diets, respectively. The odds of postdiet remission versus nonremission were 5.6-fold higher (P = .05) on elemental versus 6-food elimination diets and 12.5-fold higher (P = .003) on elemental versus directed diets and were not significantly different (P = .22) on 6-food elimination versus directed diets. After 116 single-food reintroductions, the negative predictive value of skin testing for remission was 40% to 67% (milk, 40%; egg, 56%; soy, 64%; and wheat, 67%).

Conclusion

All 3 dietary therapies are effective; however, an elemental diet is superior at inducing histologic remission compared with 6-food elimination and skin test–directed diets. Notably, an empiric 6-food elimination diet is as effective as a skin test–directed diet. The negative predictive values of foods most commonly reintroduced in single-food challenges are not sufficient to support the development of dietary advancement plans solely based on skin test results.

Le texte complet de cet article est disponible en PDF.

Key words : Eosinophilic esophagitis, eosinophils, histologic remission, pediatric, dietary therapy, food allergy, negative predictive values, elemental diet, 6-food elimination diet, skin test–directed elimination diet

Abbreviations used : APT, CCED, CCHMC, EGID, EGD, EoE, hpf, NPV, SFED, SPT


Plan


 Supported by the Campaign Urging Research for Eosinophilic Disease (CURED), the Buckeye Foundation, the International Group of Eosinophilic Researchers (TIGER), an Institutional Clinical and Translational Science Award, and National Institutes of Health (NIH)/National Center for Research Resources grant no. 5UL1RR026314. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
 Disclosure of potential conflict of interest: J. P. Abonia has received research support from the National Institutes of Health (NIH), Ception Therapeutics, and the Children’s Digestive Health and Nutrition Foundation. M. E. Rothenberg has an equity interest in Teva Pharmaceutical Industries’ reslizumab; is Chief Scientific Officer of Immune Pharmaceuticals; is inventor of several patents related to EoE that are being considered for commercial development; is on the American Partnership for Eosinophilic Disorders Medical Advisory Board; and is on the Steering Committee of the International Eosinophil Society (IES) and the International Group of Eosinophilic Researchers (TIGER). The rest of the others declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 6

P. 1570-1578 - juin 2012 Retour au numéro
Article précédent Article précédent
  • Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome
  • Chun-Yu Wei, Wen-Hung Chung, Hsiao-Wen Huang, Yuan-Tsong Chen, Shuen-Iu Hung
| Article suivant Article suivant
  • Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa
  • Stephanie A. Leonard, Gustavo Martos, Wei Wang, Anna Nowak-Węgrzyn, M. Cecilia Berin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.